You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
諾誠健華-B(09969.HK)與Incyte宣佈就Tafasitamab達成大中華區合作和許可協議
格隆匯 08-17 07:06

格隆匯8月17日丨諾誠健華-B(09969.HK)發佈公吿,諾誠健華和Incyte公司(納斯達克股票代碼:INCY)今日聯合宣佈,諾誠健華旗下一家子公司和Incyte公司就一款靶向CD19的Fc結構域優化的人源化單克隆抗體tafasitamab在大中華區的開發和商業化簽訂了合作和許可協議。

根據協議條款,諾誠健華將向Incyte支付3500萬美元首付款。此外,Incyte有資格獲得至多8250萬美元潛在的開發、註冊和商業化里程碑付款,以及分級銷售分成。諾誠健華將獲得tafasitamab在大中華區(中國內地、中國香港、中國澳門和中國台灣)在血液瘤和實體瘤開發及獨家商業化的權利。

“此次與諾誠健華合作將加速雙方合作藥物在中國的發展。”Incyte首席執行官Hervé Hoppenot説:“我們相信,諾誠健華將成為我們卓越的合作伙伴,有助於加速tafasitamab的開發。Tafasitamab將來獲批後,將有助於把這種創新療法提供給大中華區的醫生和患者。”

“我們很榮幸也很高興能和Incyte展開合作。Tafasitamab已經在美國獲批,我們將致力於推進tafasitamab在中國的獲批,造福大中華區患者。雙方的戰略合作不僅將增強我們在血液瘤和實體瘤領域的實力,也為探索BTK抑制劑奧布替尼和tafasitamab聯合用藥造福更多患者提供了良好的機會。”諾誠健華聯合創始人、董事長兼首席執行官崔霽松博士説:“我們相信,新型CD19抗體藥物tafasitamab對於增強我們大分子管線實力的長期發展戰略十分重要。我們也將迅速探索tafasitamab與我們現有產品管線聯合用藥的潛力,更好地發揮協同效應。”這一交易將在雙方合作和許可協議開始執行時即刻生效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account